{"filing":{"accession_number":"0001339970-26-000051","cik":"0001339970","ticker":"ATYR","company_name":"aTYR PHARMA INC","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"atyr-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-20260807.htm"},"events":[{"id":26173,"run_id":23771,"accession_number":"0001339970-26-000051","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"aTyr Pharma issued a press release on August 7, 2026 announcing second quarter 2026 financial results, including condensed consolidated statements of operations and balance sheets. The filing discloses Q2 2026 R\u0026D expenses of $6.7 million, G\u0026A expenses of $4.1 million, net loss of $10.3 million, and cash position of $58.9 million as of June 30, 2026. This is a standard quarterly earnings release furnished under Item 2.02.","company_name":"aTYR PHARMA INC","ticker":"ATYR","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27202,"accession_number":"0001339970-26-000051","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"aTyr Pharma issued a press release on August 7, 2026 announcing second quarter 2026 financial results, including condensed consolidated statements of operations and balance sheets. The filing discloses Q2 2026 R\u0026D expenses of $6.7 million, G\u0026A expenses of $4.1 million, net loss of $10.3 million, and cash position of $58.9 million as of June 30, 2026. This is a standard quarterly earnings release furnished under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:11:27.889027+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27202,"accession_number":"0001339970-26-000051","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"aTyr Pharma issued a press release on August 7, 2026 announcing second quarter 2026 financial results, including condensed consolidated statements of operations and balance sheets. The filing discloses Q2 2026 R\u0026D expenses of $6.7 million, G\u0026A expenses of $4.1 million, net loss of $10.3 million, and cash position of $58.9 million as of June 30, 2026. This is a standard quarterly earnings release furnished under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:11:27.889027+00:00","company_name":"aTYR PHARMA INC","ticker":"ATYR","filing_date":"2026-08-07"}]}